STM JOURNALS

Research & Reviews: A Journal of
Toxicology

https://journals.stmjournals.com/rrjot/

ISSN: 2231-3834 (Online)
ISSN: 2349-1264 (Print)
Volume 14, Issue 3, 2024
September–December
DOI (Journal): 10.37591/RRJoT

Review RRJoT

Pharmacovigilance and Drug-Induced Toxicities: A Clinical Perspective

Robin Sijo[1,*], Jenefa Melcy[2], Kamalesh[3], Shivani[4], Jagath[5]

Abstract

Pharmacovigilance, which aims to detect, assess, and prevent medication-induced toxicities and adverse drug reactions, is a crucial part of healthcare. This study examines several kinds of drug-induced toxicities, such as idiosyncratic, dose-dependent, and allergic reactions, and emphasizes the function of clinical pharmacists in the tracking and treatment of these illnesses. Pharmacovigilance systems are crucial because they can identify and handle drug-related safety issues that might not surface during clinical trials. This is especially true in the post-marketing phase. One important component of tailoring medication treatments to reduce adverse drug reactions is pharmacogenetics, which focuses on genetic variations influencing drug metabolism. Drug interactions with other drugs and how they affect toxicities are also looked at. Artificial intelligence and machine learning are examples of technological breakthroughs that are positioned by automating data analysis and forecasting possible toxicities, you can transform adverse drug reaction detection. International cooperation and real-time monitoring systems are essential for improving pharmacovigilance initiatives globally and guaranteeing prompt adverse drug reaction reporting and handling. The need for proactive pharmacovigilance strategies to enhance patient safety, maximize therapeutic outcomes, and save healthcare costs is highlighted by this research. Artificial intelligence and machine learning represent transformative advancements that enhance pharmacovigilance by automating data analysis and predicting potential adverse drug reactions. By leveraging these technologies, the detection of adverse drug reactions can be significantly improved, facilitating timely responses and interventions. Moreover, fostering international collaboration and establishing real-time monitoring systems are critical for bolstering global pharmacovigilance efforts, ensuring that adverse drug reactions are reported and managed promptly. This research underscores the necessity of adopting proactive pharmacovigilance strategies to enhance patient safety, optimize therapeutic outcomes, and reduce healthcare costs, ultimately leading to more effective healthcare delivery and improved public health outcomes.

Keywords: Pharmacovigilance, adverse drug reactions (ADRs), pharmacogenetics, drug-induced toxicities, patient safety

***Author for Correspondence**
Robin Sijo
E-mail: robinsijo777@gmail.com

[1–5]Pharm D. Intern, Department of Pharmacy, Cherraan's College of Pharmacy, 521, Siruvani Main Road, Telungupalayam Pirivu, Coimbatore, Tamil Nadu, India

Received Date: October 21, 2024
Accepted Date: October 22, 2024
Published Date: November 19, 2024

Citation: Robin Sijo, Jenefa Melcy, Kamalesh, Shivani, Jagath. Pharmacovigilance and Drug-Induced Toxicities: A Clinical Perspective. Research & Reviews: A Journal of Toxicology. 2024; 14(3): 17–30p.

INTRODUCTION

Pharmacovigilance (PV), which focuses on the identification, evaluation, comprehension, and prevention of adverse drug reactions (ADRs) and other drug-related issues, is an essential part of contemporary healthcare. PV, according to the World Health Organization (WHO), is "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems." Through comprehensive post-marketing monitoring of drug safety profiles, this discipline plays a crucial role in assuring patient safety and enhancing

© STM Journals 2024. All Rights Reserved

therapeutic outcomes [1]. It is impossible to overestimate the significance of PV, especially considering the constant release of new drugs. Clinical studies offer preliminary safety and effectiveness information, but they sometimes only include a small number of participants and are not long enough to detect all possible side effects [2]. Finding drug-induced toxicities is more likely as more people use medications, frequently including patients with various comorbidities and polypharmacy. These toxicities might be modest or severe, and they can have a big effect on healthcare expenses and patient quality of life [3]. Idiosyncratic reactions, organ toxicity, and allergy reactions are just a few of the ways that drug-induced toxicities might appear. Clinically important examples include heart toxicity linked to specific chemotherapeutic drugs and hepatotoxicity from acetaminophen abuse. Given the potential for major consequences, prolonged hospital stays, or even death, healthcare providers must have a thorough understanding of these toxicities [4]. Furthermore, limiting risks and guaranteeing the best possible treatment regimens depend on the prompt detection and handling of ADRs. Clinical pharmacists are essential in the identification and handling of ADRs, applying their specific pharmacological expertise to improve patient safety. Reviewing prescription schedules, evaluating possible drug interactions, and advising patients on how to take medications safely are some of their duties. Clinical pharmacists are important participants in PV initiatives since they are frequently at the forefront of patient monitoring for indications of ADRs [5]. They can encourage timely reporting of adverse events by working with doctors and other healthcare professionals, which is essential for updating medication safety data and guiding future prescription practices. Clinical pharmacists also play a key role in informing patients and medical professionals about the dangers of prescription drugs. They emphasize the significance of reporting any negative effects and offer training on recognizing the signs of ADRs. Since more awareness among healthcare teams might result in higher detection rates and better management methods for drug-induced toxicities, this teaching function is crucial [6].

In summary, PV, which aims to maximize patient outcomes and ensure drug safety, is a crucial component of healthcare. Drug-induced toxicities provide substantial difficulties in clinical practice, emphasizing the necessity of aggressive management and ongoing monitoring. Clinical pharmacists are crucial resources in this field, helping to identify, evaluate, and treat ADRs. By encouraging a culture of safety within healthcare systems, their participation not only improves patient safety but also advances the larger objectives of PV (Figure 1).



Figure 1. PV workflow [7].

DRUG-INDUCED TOXICITY: AN OVERVIEW

Pharmacological substances can cause unpleasant effects known as drug-induced toxicities, or DITs. These toxicities might have everything from minor side effects to potentially fatal situations.

© STM Journals 2024. All Rights Reserved

Drug interactions, patient-specific features, and the chemical makeup of medications are some of the variables that contribute to the diversity in DITs. An outline of the main categories of medication-induced toxicities, the drug classes linked to these toxicities, and a few significant case studies are provided below.

Types of Drug-Induced Toxicity (Table 1)

- *Dose-Dependent Toxicity:* Dose-dependent toxicities happen when the effects of a medication intensify with increasing dosage. The pharmacological activity of the medication causes these reactions, which are typically predictable. Examples include renal toxicity from large dosages of aminoglycosides and liver damage from acetaminophen overdose [8].
- *Idiosyncratic Toxicity:* Unpredictable idiosyncratic toxicities happen in a tiny proportion of patients and are frequently brought on by inherited tendencies. These side effects could take some time to show up and are not related to the drug's dosage. For example, idiosyncratic hypersensitivity reactions occur to anticonvulsants, such as carbamazepine [9].
- *Allergic (Hypersensitivity) Toxicity:* Drug-induced allergic toxicities are reactions mediated by the immunological system. These may show up as minor side effects like skin rashes or serious side effects like anaphylaxis. Penicillin in particular is frequently linked to allergy reactions when used as an antibiotic [10].
- *Carcinogenic and Teratogenic Toxicity:* Certain medications have the potential to cause teratogenesis, fetal abnormalities, carcinogenesis, and the development of cancer. Immunosuppressants and chemotherapy treatments can raise the risk of cancer, and medications like thalidomide are known to cause birth abnormalities [11, 12].

Table 1. Common drugs and associated toxicities.

Drug	**Toxicity**
Doxorubicin	Cardiotoxicity
Carboplastin, isplastin	Renal toxicity
Vincristine	Intestinal ileus
L-asparaginase	Hypersensitivity reaction
Cyclophosphamide	Sterile hemorrhagic cystitis
Rabacfosadine (tanovea)	Dermatologic toxicity, pulmonary fibrosis
CCNU (lomustine)	Hepatoxicity

Common Classes of Drugs Associated with Toxicities

- *Antibiotics Toxicity Types:* Nephrotoxicity, ototoxicity, hypersensitivity examples: aminoglycosides are linked to nephrotoxicity and ototoxicity, while beta-lactams like penicillin are common causes of allergic reactions.
- *Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Toxicity Types:* Gastrointestinal (GI) bleeding, renal impairment Examples: Long-term NSAID use, such as ibuprofen, can result in gastric ulcers and kidney dysfunction due to the inhibition of prostaglandin synthesis [13].
- *Anticancer Drugs (Chemotherapeutics) Toxicity Types:* Bone marrow suppression, cardiotoxicity, nephrotoxicity examples: doxorubicin is associated with cardiotoxicity, while cisplatin can cause nephrotoxicity [14, 15].
- *Antipsychotics and Anticonvulsants Toxicity Types:* Hepatotoxicity, neurotoxicity examples: valproic acid, an anticonvulsant, can induce hepatotoxicity, and lithium, used in mood disorders, may cause neurotoxicity at high concentrations [16, 17].

CASE STUDIES OF SIGNIFICANT ADRS IN CLINICAL PRACTICE

Case Study 1

A 22-year-old woman who experienced SJS/TEN overlap brought on by carbamazepine throughout her pregnancy and recovered. Due to her history of epilepsy, our patient was currently taking sodium

© STM Journals 2024. All Rights Reserved

valproate. This problem was brought on by our patient switching to carbamazepine because of its minimal teratogenicity. The diagnosis was aided by a history of prodromal symptoms and carbamazepine exposure. The patient experienced great success with carbamazepine cessation and a multimodal approach to symptomatic care [18].

Case Study 2

Statin-induced rhabdomyolysis – A sixty-year-old female patient reported experiencing soreness in her muscles and dark urine after an increase in her statin dosage (simvastatin). Elevated creatine kinase levels in the laboratory confirmed the diagnosis of rhabdomyolysis, a rare but dangerous statin side effect. The patient recovered well when the medicine was stopped, and intravenous fluids were given [19].

Both random (idiosyncratic) and predictable (dose-dependent) pathways can result in drug-induced toxicities. Severe adverse medication reactions are often associated with common drug classes, such as antibiotics, NSAIDs, and chemotherapeutics. Clinicians must be vigilant in monitoring patients, particularly those on high-risk medications, to minimize the risk of significant toxicities.

MECHANISMS OF DRUG-INDUCED TOXICITIES

Both pharmacokinetic and pharmacodynamic variables may contribute to toxicity in medication. The mechanisms of drug absorption, distribution, metabolism, and excretion (ADME) are covered by pharmacokinetics, changes in these procedures may result in higher medication levels in the body, which will increase toxicity. For example, decreased liver function can inhibit the metabolism of medications, especially those that are broken down by cytochrome P450 enzymes. This can lead to increased plasma levels and possible side effects. Drugs that are mostly eliminated by the kidneys may accumulate because of impaired drug clearance caused by decreased renal function, which raises the risk of toxicity. The study of pharmacodynamics looks at how medications work in the body, with a particular emphasis on how they interact with receptors. When a medication's therapeutic effects or interactions with undesired targets occur, toxicity may occur. As an illustration of how pharmacodynamic characteristics might contribute to hazardous effects, opioid analgesics, for instance, can cause respiratory depression if dosed incorrectly or if a patient is extremely sensitive [20].

Pharmacogenomics

Genetic factors affecting ADR susceptibility pharmacogenomics is essential to comprehending how each person reacts to medications, especially when it comes to ADRs. The safety, effectiveness, and metabolism of drugs can all be greatly impacted by genetic diversity. For instance, variations in the gene CYP2D6 impact how many different drugs are metabolized. While ultra-rapid metabolizers might not have therapeutic effects, poor metabolizers might have raised drug levels, which could enhance toxicity. Serious hypersensitivity reactions are also associated with specific genetic variants in the HLA gene area. People with certain HLA alleles, for example, are more likely to experience severe cutaneous side effects when taking medications like allopurinol or carbamazepine. By lowering the risk of ADRs and improving therapeutic results, knowledge of these genetic markers can assist in customizing medicine selections [21].

Drug–Drug interactions (DDIs)

Which can happen via pharmacokinetic or pharmacodynamic pathways. One medication may have an impact on another's absorption, distribution, metabolism, or excretion through pharmacokinetic interactions. For instance, metronidazole, an antibiotic, can prevent the metabolism of warfarin, increasing the anticoagulant effects and risk of bleeding [22].

Pharmacotherapy optimization requires an understanding of how pharmacokinetics, pharmacodynamics, and genetic variables contribute to medication toxicity. Pharmacogenomics offers

© STM Journals 2024. All Rights Reserved

information that can help guide customized medicine, enabling medical professionals to select medications according to each patient's unique genetic profile. Improving patient safety also requires identifying and controlling possible DDIs. Healthcare practitioners can increase therapeutic efficacy while lowering the possibility of side effects by taking care of these elements.

ROLE OF PV SYSTEMS

Historical Development of PV

The research and practices involved in the identification, evaluation, and avoidance of ADRs and other drug-related issues are collectively referred to as PV. With the creation of its International Drug Monitoring Program in 1968, the WHO officially began PV efforts to coordinate ADR reporting globally [23]. This was a reaction to the 1960s thalidomide disaster, which brought attention to the necessity of medication safety monitoring. The Pharmacovigilance Program of India (PVPI), introduced by the Central Drugs Standard Control Organization (CDSCO) in 2010, is a vital component of drug safety surveillance [24] in India. Since the inception of the Adverse Event Reporting System (AERS), which was subsequently superseded by the FDA Adverse Event Reporting System (FAERS) [25], the United States Food and Drug Administration (FDA) has been at the forefront of PV. Together, these groups have accelerated the development of PV into an essential element of public health systems throughout the world (Figure 2).



Figure 2. Graph showing the global distribution of ADR reporting [26].

OVERVIEW OF PV TOOLS

Many platforms and tools have been created to improve PV efforts. A crucial component is spontaneous reporting systems (SRS), which allow the public and medical professionals to freely report ADRs to regulatory bodies [27]. The main source of information for probable safety issues early signal identification is these reports. The European Medicines Agency (EMA) developed EudraVigilance, a sophisticated system for tracking and evaluating data on suspected ADRs throughout Europe [28]. It is essential to the centralized oversight of medication safety throughout the EU. Globally speaking, VigiBase, which is run by the Uppsala Monitoring Center (UMC) in Sweden, is the biggest database of ADR reports. It gathers information from more than 170 nations that take part in the WHO Program for international drug monitoring [29]. These instruments are essential for guaranteeing prompt signal identification, evaluating medication benefit-risk ratios, and carrying out regulatory actions when required.

Challenges Faced in PV

Even with PV's advancements, several problems still exist. The underreporting problem is one of the most important ones. Only a small percentage of ADRs, between 6% and 10%, according to studies, are reportedly reported using SRSs [30]. This causes a delay in the identification of signals, which could endanger patients. Furthermore, the quality of the data that is submitted is frequently subpar, lacking details, or inconsistent, making evaluation difficult [31]. The underreporting issue is further exacerbated in underdeveloped nations due to frequently insufficient resources and low knowledge of PV practices [32]. Additional difficulties include the requirement for sophisticated

© STM Journals 2024. All Rights Reserved

analytics to handle and analyze the enormous volumes of data produced by PV systems [33] and the difficulty of incorporating real-world data from diverse sources, such as social media and electronic health records, into preexisting frameworks [34]. More international collaboration, improved healthcare provider education regarding the significance of reporting ADRs, and the creation of new technologies to enhance data quality and analytics are all necessary to meet these challenges (Table 2) [2].

Table 2. Summary of PV tools and their characteristics.

Category	**PV tools**
SRS	FDA AE reporting system – US
	EudraVigilance – EMA
	VigiBase – UMC
Electronic health records and medical databases	Sentinel system – US
	CPRD – UK
Databases for signal detection	VigiLyze – WHO
	SRS analyzer
Risk management plans	Patient registries
	Post-marketing studies
Social media monitoring tools	MEDWATCHER
	Data mining algorithms
Mobile health (mHEALTH) and mobile application	MEDSAFETY APP
	Yellow card app – UK, MHRA
Artificial intelligence (AI) and machine learning (ML) tools	RODS
	DeepPV

CLINICAL PERSPECTIVES ON ADR DETECTION AND REPORTING

Pharmacists play a vital role in reducing ADRs by detecting, assessing, and reporting them. Research by Khalili et al. Demonstrated that pharmacist involvement increased ADR reporting. A study in Iran found that clinical pharmacy residents significantly improved ADR reporting, identifying 54 serious reactions. In India, clinical pharmacists identified ADRs as the primary drug-related issue, with an incidence of 0.082%. Their active participation in reporting ADRs leads to quicker management, ultimately reducing morbidity and mortality associated with these reactions. This highlights the importance of pharmacists in enhancing medication safety and patient outcomes [35]. The CDSCO has launched a comprehensive national PV Program, following the WHO guidelines for establishing robust PV systems. This initiative aims to collect extensive data on ADRs within the Indian population and share findings with the global healthcare community through the WHO-UMC. By fostering a highly participative approach, the program seeks to enhance drug safety monitoring, ultimately improving patient outcomes and contributing to worldwide efforts in PV. This initiative underscores India's commitment to addressing medication safety and promoting public health [36]. Following the establishment of the international drug monitoring Program, the WHO-UMC has created a global PV network across over 150 countries. As a full member, India has developed a robust PV system through the PVPI, which includes multiple ADR monitoring centers. After quality checks of individual case safety reports (ICSRs), India submits this data to the UMC using the web-based tool Vigiflow®. The collected information is then stored in Vigibase®, serving as the global repository for ICSR data, enhancing drug safety monitoring and reporting worldwide [37]. Magicoder streamlines the encoding of ADR reports by allowing pharmacologists to review and validate proposed MedDRA terms instead of selecting from 70,000 low-level terms. This efficiency not only reduces the time required for encoding but also enhances the quality of subsequent data analysis, improving overall PV outcomes [38]. A safety signal refers to newly reported or established side effects linked to medications that require further investigation. The primary goal is to identify unknown potential adverse effects using various databases and technologies. Healthcare practitioners

© STM Journals 2024. All Rights Reserved

and regulatory agencies utilize these resources to monitor and analyze adverse occurrences. The FDA maintains a comprehensive database of adverse event reports through its AERS. Additionally, the WHO's VigiBase and EudraVigilance capture potential adverse medication responses from multiple countries. PV employs statistical and data mining techniques to identify patterns and relationships in PV data. Methods include the Multi-Item Gamma Poisson Shrinker, Bayesian Confidence Propagation Neural Network, Reporting Odds Ratio, and Proportional Reporting Ratio. Software tools for signal detection include VigiLyze from the UMC, Empirica Signal from Oracle, and the R-based tool openEBGM. Assessing safety signals is vital for ongoing PV, ensuring that regulatory bodies have the latest data on a medication's benefits and risks [39]. Currently, there is no universally accepted method for assessing the causality of ADRs. Various methods exist for this purpose, including the WHO-UMC causality categories and Naranjo's probability scale, which are the most used. Other approaches include probability calculations based on Bayes' theorem, Bénichou's group method, French imputation systems, the European ABO systems, and several algorithms, such as Jones', Karch, and Lasagna, and Gallagher's algorithms. Each method offers a different framework for evaluating the relationship between medications and reported ADRs, but consensus on a standard remains elusive (Figure 3 & Table 3) [40].

Table 3. Country wise data bases and ADR forms [40].

Country	Regulatory Agency	Data Base	ADR form
USA	FDA	AERs.	MedWatch.
Europe	EMEA	EudraVigilance.	–
Uk	MHRA	–	Yellow card.
India	CDSCO	VigiFlow.	Suspected ADR form.
Japan	PMDA	–	–
Australia	TGA	–	Blue card.
Singapore	HAS	–	ADR watch.
Canada	HC	Canada vigilance.	Canada vigilance reporting form.
Malaysia	NPCB	–	–
Saudi Arabia	SFDA	–	–
Brazil	ANVISA	–	–
China	SFDA	–	–

IMPACT OF DRUG-INDUCED TOXICITIES ON PATIENT SAFETY

Patients experiencing ADR during hospitalization stayed significantly longer than those without ADRs. (median stay:15 versus 8 days respectively) [42]. An ADR is associated with a significantly prolonged length of stay and almost 2-fold increased risk of death [43]. ADRs are one of the major causes of hospital admission and in-hospital morbidity, they have become an important clinical problem and a constant concern of the public healthcare systems accounting for up to 5% of hospital admissions, 28% of emergency visits and 5% of hospital deaths with associated costs of economic burden. Therefore, timely and accurate detection of adverse reactions is critical in improving patient's safety and therefore reducing healthcare costs [44].

ADRs may increase costs due to increased hospitalization, prolongation of hospital stays, and additional clinical investigations in more serious cases. The main costs of ADRs in a hospital are wages, disposable goods, and medications. Aside from the direct financial costs, there are also several indirect costs for patients and their caregivers that are incurred by ADRs, such as missed days from work and/or morbidity, such as anxiety due to the ADR episode [45].

In terms of legal considerations, much can be said in favor of developing healthcare no-fault laws. Major legal consideration should be given to the informed consent of the patient when using drugs that have undesirable side effects. Informed consent should include the patient appraisal of the

© STM Journals 2024. All Rights Reserved

risk/benefit ratio [43]. Recently public health ethics is an emerging discipline that focuses on addressing ethical issues related to research or interventions that are to be considered not only at the individual level but also concerning the health of the population at large or in groups (Figure 4) [44].



Figure 3. Overview of ADR monitoring in India [41].



Abbreviations: ADE = adverse drug events; Int$ = international dollars.

Figure 4. The average monthly cost of illness of respondents based on reported adverse drug events status and healthcare attendance, is divided into direct and indirect costs [46].

© STM Journals 2024. All Rights Reserved

PV IN THE POST-MARKETING PHASE

Importance of Continued Monitoring Post-Regulatory Approval

For a pharmaceutical company, to market a drug or any form of medicinal product, the product should have a favorable benefit-to-harm ratio for drug regulatory authorities to authorize. The problem is that it only lies on limited evidence from premarketing studies. During this period, long-term or uncommon side effects may not be detected. So, if such reactions are identified after approval, with the help of continued monitoring they could be detected. The regulators and manufacturers can then take the required actions to allow the drug in the market or completely withdraw the product, they could also include "specific warnings" in the product label.

The time between the launch date of the product and reports of adverse reactions which made the process of product withdrawal from the market is shortening over the years. This signifies the importance and success of continued monitoring by the PV [47].

Even though the drug is introduced into the market after the safety and efficacy test, the actual risk involved with the product is known only when it enters the market. So, it is important to recognize the risk involved with the drug when it enters the market. It is also important to remember that special age groups, such as children, elderly, and pregnant women are often not included in the premarketing studies. This demands the need for post-marketing PV. It significantly improves the ability to identify the unidentified ADRs [48].

Timeline Showing Drug Withdrawal Due to Post-Marketing ADRs

The study conducted by Igho J. Onakpoya, Carl J. Heneghan, and Jeffrey K. Aronson identified 462 medicinal products that were withdrawn from the market between 1953 and 2013, the most common reason being hepatotoxicity. The supporting evidence is mainly composed of 72% of anecdotal reports. The interval between the first reported adverse reaction and the year of first withdrawal was 6 years (Figure 5) [49].

Figure 5. Case study timeline showing drug withdrawals due to post-marketing ADRs [47].

© STM Journals 2024. All Rights Reserved

Examples Where Post-Marketing Surveillance Identified Significant Toxicities

Troglitazone used to treat Type 2 Diabetes was withdrawn from the market in 2000 after cases of liver damage were reported during post-market surveillance [50]. Cerivastatin used to lower cholesterol was withdrawn from the market in 2001 because of 52 deaths associated with rhabdomyolysis which ultimately led to kidney failure [51]. Sibutramine used as a weight loss medication had some unfavorable effects on the cardiovascular system due to a higher incidence of cardiovascular events and was withdrawn in 2010 [52]. Rofecoxib used as an NSAID for pain management was withdrawn from the market in 2004 after post-marketing studies revealed significantly higher risks of heart attack and strokes in long-term users [53]. Thalidomide used as a sedative and to treat morning sickness was withdrawn in the 1960s due to severe birth defects when taken during pregnancy but later reintroduced with restricted use for specific conditions (Table 4) [54].

Table 4. Post-marketing surveillance case examples**.**

Drug	Indication	ADR	Withdrawn Year
Troglitazone	Anti-diabetic	Severe liver toxicity	2000
Cerivastatin	Lowering cholesterol	Rhabdomyolysis	2001
Sibutramine	Weight loss	Increased risk of heart attack	2010
Rofecoxib	NSAID	Cardiovascular risks	2004
Thalidomide	Sedative	Birth defects	1960s

FUTURE DIRECTIONS IN PV

PV is a crucial part of global healthcare systems, aiming to monitor, assess, and prevent ADRs. The rapidly evolving field of medicine, combined with technological advances, demands more effective ways to predict and mitigate drug-induced toxicities. Innovations in AI, pharmacogenetics, and global collaborations are paving the way for future directions in PV systems.

ROLE OF AI AND ML IN PREDICTING ADRS

AI and ML are transforming PV by enhancing ADR detection and prediction capabilities. Traditional methods rely on SRSs, which are often plagued by underreporting and delayed signal detection. AI-driven systems can automate data collection from electronic health records (EHRs), clinical trials, and even social media platforms to detect potential ADRs earlier and more accurately. ML algorithms, particularly deep learning, and neural networks have been used to predict ADRs by analyzing large datasets and identifying hidden patterns that would typically be missed by human analysis [55]. These technologies are capable of continuously learning from real-world data, enabling a dynamic approach to ADR prediction and improving the overall safety monitoring process. For example, the use of AI in natural language processing (NLP) has been effective in screening unstructured data from EHRs, identifying ADRs with high sensitivity and specificity [56].

Potential of Pharmacogenetics and Personalized Medicine in Drug-Induced Toxicities

Pharmacogenetics, the study of how an individual's genetic makeup influences drug response, holds great promise in minimizing drug-induced toxicities. ADRs often result from genetic variations affecting drug metabolism, transport, and receptor targets. By integrating pharmacogenetic data into clinical decision-making, healthcare professionals can tailor treatments to individual genetic profiles, significantly reducing the risk of ADRs [57]. Personalized medicine leverages these insights to adjust drug dosages or select alternative medications, thereby improving therapeutic outcomes and safety [58]. This personalized approach is particularly beneficial in drugs with narrow therapeutic indices, where slight variations in dose can lead to toxicity. In the future, as more pharmacogenetic data become available, personalized medicine will likely become a standard aspect of PV practices, enhancing the precision of ADR prediction and prevention.

Improving PV Systems Through Global Collaboration and Integration

Global collaboration is another key factor in advancing PV systems. ADRs are a global issue, as medications are widely distributed across different regions, with diverse populations being exposed to

© STM Journals 2024. All Rights Reserved

the same drugs. A coordinated global approach is essential to address ADRs effectively, ensuring that safety signals are detected early and shared across borders [2]. International organizations like the WHO and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) have played pivotal roles in facilitating this exchange of information through initiatives like the WHO Program for International Drug Monitoring and the establishment of the ICH E2E guidelines [59]. Moving forward, the integration of global PV systems, supported by advances in data-sharing technologies, will improve the efficiency of ADR reporting and analysis, enabling a more comprehensive understanding of drug safety profiles worldwide.

Furthermore, regulatory harmonization across different regions will ensure that safety standards and reporting mechanisms are consistent. As countries strengthen their PV frameworks, the collective experience and shared data will contribute to a more robust global system capable of managing drug-induced toxicities more effectively (Figure 6) [60].

Figure 6. AI applications in PV [61].

CONCLUSIONS

In summary, PV, which addresses drug-induced toxicities and ADRs remains a vital component of ensuring patient safety. Proactive PV plays an increasingly important role in discovering, evaluating, and managing these risks as the healthcare landscape changes with new therapies and technology. Clinical pharmacists' involvement in ADR monitoring increases drug-induced toxicity management and detection rates, which lowers hospital stays and related medical expenses. With the help of AI and ML, pharmacogenetic insights and real-time data analytics can be integrated to improve drug safety and enable personalized therapy. In the future, international cooperation and ongoing post-marketing surveillance will be necessary to guarantee the prompt detection of dangers associated with drugs, which will eventually enhance patient outcomes and the general safety of therapeutic treatments.

REFERENCES

1. World Health Organization. Pharmacovigilance. [Internet]. Available at https://www.who.int/activities/pharmacovigilance
2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1251–6.

© STM Journals 2024. All Rights Reserved

3. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc. 2020;21(2):181–7.
4. Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5(1):58.
5. Eid M, Alotaybi J, Alanazi MA, Hadadi SM, Alanazi K, Alotaibi AT. The role of clinical pharmacy in improving medication management within the primary care team. [Internet]. Available at https://mavink.com
6. Maclure M. The case-crossover design: a method for studying transient exposures. Annu Rev Public Health. 1991;12:331–53.
7. Pharmacovigilance system flow chart. Mavink.com [Internet]. 2023. Available at https://mavink.com/pharmacovigilance-system
8. Chidiac AS, Buckley NA, Noghrehchi F, Cairns R. Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease. Expert Opin Drug Metab Toxicol. 2023;19(5):297–317.
9. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia. 1998;39:7–12.
10. Casimir-Brown RS, Kennard L, Kayode OS, Siew LQC, Makris M, Tsilochristou O, et al. Piperacillin-Tazobactam hypersensitivity: a large, multicenter analysis. J Allergy Clin Immunol Pract. 2021;9(5):2001–9.
11. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94(3):182–92.
12. Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embry Tod. 2015;105(2):140–56.
13. Domper Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf. 2022;21(3):373–84.
14. Khairnar SI, Kulkarni YA, Singh K. Cardiotoxicity linked to anticancer agents and cardioprotective strategy. Arch Pharm Res. 2022;45(10):704–30.
15. Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7(1):44735.
16. Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4(1):27.
17. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–44.
18. Shrestha O, Pant P, Devkota N, Gurung D, Shrestha DB. Carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome overlapping during pregnancy in a South-East Asian patient: a case report. Ann Med Surg. 2021;68:102624.
19. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–90.
20. Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia (PA): Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
21. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119–37.
22. Roberts AG, Gibbs ME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol. 2018;10:123–34.
23. World Health Organization. The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva: World Health Organization; 2006. Available at https://www.who.int/publications-detail-redirect/9241593915
24. Singh P, Vaishnav Y, Verma S. Development of pharmacovigilance system in India and paradigm of pharmacovigilance research: an overview. Curr Drug Saf. 2023;18(4):448–64.

© STM Journals 2024. All Rights Reserved

25. U.S. Food and Drug Administration (FDA). FDA Adverse Event Reporting System (FAERS) Public Dashboard. [Internet]. Available at https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
26. Endrikat J, Vogtlaender K, Dohanish S, Balzer T, Breuer J. Safety of gadobutrol: results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol. 2016;51(9):537–43.
27. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.
28. European Medicines Agency. EudraVigilance system overview. 2016. Available at https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance
29. VigiBase: WHO's global database. Uppsala Monitoring Centre [Internet]. Available at https://www.who-umc.org/global-pharmacovigilance/vigibase/
30. Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2017;83(4):875–83.
31. World Health Organization. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety. Available at https://www.who.int/teams/regulation-prequalification/pharmacovigilance
32. Kabore L, Millet P, Fofana S, Berdai D, Adam C, Haramburu F. Pharmacovigilance systems in developing countries: an evaluative case study in Burkina Faso. Drug Saf. 2013;36(5):349–58.
33. Harpaz R, Vilar S, DuMouchel W, et al. Combining signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20(3):413–9.
34. Wang SV, Schneeweiss S. Assessing and interpreting real-world evidence studies: introductory points for new reviewers. Clin Pharmacol Ther. 2022;111(1):145–9.
35. Alqurbi M, Atiah M. The role of clinical pharmacists in reducing adverse drug reactions. Int J Med Dev Ctries. 2020;4(1):236–9.
36. Banerjee P. Pharma technology latest regulatory guidelines and the process of ADR reporting in India. World Res J Pharmacovigil. 2018;1(1).
37. Prakash J, Sachdeva R, Shrivastava TP, Jayachandran CV, Sahu A. Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India. Indian J Pharmacol. 2021;53(2):143–52.
38. Combi C, Zorzi M, Pozzani G, Moretti U, Arzenton E. From narrative descriptions to MedDRA: automagically encoding adverse drug reactions. J Biomed Inform. 2018; 84:184–99.
39. George J, Dsouza PL, Jahnavi Y, Singh H, Kumar PA. Databases and tools for signal detection of drugs in post-marketing surveillance. In: Signal analysis in pharmacovigilance. 1st ed. Boca Raton (FL): CRC Press; 2024. p. 12.
40. Kumar A, Khan H. Signal detection and their assessment in pharmacovigilance. Open Pharm Sci J. 2015;2(1):66–73.
41. Sahu A, Das NR. ADR monitoring and reporting in India. Indian J Pharm Pract. 2024;17(3):198–204.
42. Akhideno PE, Fasipe OJ, Isah AO, Owhin OS. Economic burden, impact, and consequence of adverse drug reactions among medical inpatients in clinical practice. J Clin Sci. 2018;15(4):186–93.
43. Herbert V. Medical, legal and ethical considerations in the use of drugs having undesirable side effects. Am J Clin Nutr. 1975;28(5):555–60.
44. Endrikat J, Vogtlaender K, Dohanish S, Balzer T, Breuer J. Safety of gadobutrol: results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol. 2016;51(9):537–43.
45. Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–7.
46. Gyllensten H, Rehnberg C, Jönsson A, Petzold M, Carlsten A, Andersson Sundell K. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open. 2013;3(6):e002574. doi:10.1136/bmjopen-2013-002574.

© STM Journals 2024. All Rights Reserved

47. Aronson JK. Post-marketing drug withdrawals: pharmacovigilance success, regulatory problems. Therapie. 2017;72(5):555–61. doi:10.1016/j.therap.2017.02.005.
48. Shetty A, Dubey A, Matcheswala A, Bangera S. Pharmacovigilance systems and strategies: importance of post-marketing surveillance for ensuring drug safety and patient health in Europe, United States, and India. Published online 2023.
49. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14(1):10. doi:10.1186/s12916-016-0553-2.
50. Babai S, Auclert L, Le-Louët H. Safety data and withdrawal of hepatotoxic drugs. Therapie. 2021;76(6):715–23. doi: 10.1016/j.therap.2021.08.006.
51. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Contr Trials Cardiovasc Med. 2001;2(5):205–7.
52. Czernichow S, Batty D. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obes Facts. 2010;3(3):155–6.
53. Oakley G. Lessons from the withdrawal of rofecoxib: observational studies should not be forgotten. BMJ. 2004;329(7478):1342.
54. Vargesson N, Stephens T. Thalidomide: history, withdrawal, renaissance, and safety concerns. Expert Opin Drug Saf. 2021;20(12):1455–7.
55. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010–21.
56. Wu S, Roberts K, Datta S, et al. Deep learning in clinical natural language processing: a methodical review. J Am Med Inform Assoc. 2020;27(3):457–70.
57. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73.
58. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–50.
59. World Health Organization (WHO). The WHO programme for international drug monitoring. Published 2021. Available at https://www.who.int/teams/regulation-prequalification/pharmacovigilance
60. Van Boxtel CJ, Santoso B, Edwards IR, editors. Drug benefits and risks: international textbook of clinical pharmacology. 2nd ed. Amsterdam: IOS Press; 2008.
61. Reddy S. Benefits of AI & automation in pharmacovigilance. Birlasoft Life Sci. 2021. Available at https://www.birlasoft.com/articles/benefits-of-ai-automation-in-pharmacovigilance.

© STM Journals 2024. All Rights Reserved